Advertisement

Search Results

Advertisement



Your search for Charlotte Bath matches 15 pages

Showing 1 - 15


colorectal cancer
issues in oncology

Fecal Immunochemical Test Sensitive and Effective for Annual Colorectal Cancer Screening

Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing the fecal immunochemical...

colorectal cancer
hepatobiliary cancer
lung cancer
lymphoma

Increased Cancer Mortality Rate Among Recipients of Solid-Organ Transplants

Solid-organ transplant recipients have a higher rate of cancer mortality than what is expected in the general population, according to a Canadian study by Acuna et al published in JAMA Oncology. Cancer mortality among transplant recipients was significantly elevated compared with data for the...

colorectal cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age May Have Increased Risk for Positive Lymph Nodes

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact...

colorectal cancer

Long-Term Thyroid Hormone Replacement Associated With Decreased Colorectal Cancer Risk

Long-term thyroid hormone replacement was associated with a decreased risk of colorectal cancer, but hyperthyroidism and untreated hypothyroidism were associated with a modestly elevated risk, according to a study using a large population-based medical records database from the United Kingdom. The...

colorectal cancer

Statin Use Not Associated With Reduced Mortality in Patients With Colorectal Cancer

Statin use was not associated with reduced mortality among patients diagnosed with primary colorectal cancer between 2003 and 2009 and followed for a median of 3.4 years in the Darmkrebs: Chancen der Verhütung durch Screening (DACHS) study, an ongoing population-based study of colorectal...

colorectal cancer
issues in oncology
issues in oncology
issues in oncology

Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer

Collaboration between surgeons and medical oncologists specialists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Hussain et al in the Journal of Oncology Practice. An increase from one to five in the...

colorectal cancer

Lower 30-Day Mortality, Increased Likelihood of Chemotherapy With Laparoscopic vs Open Colectomy for Stage III Colon Cancer

“In routine clinical practice, laparoscopic colectomy is associated with lower 30-day mortality, shorter length of stay, and greater likelihood of adjuvant chemotherapy initiation among stage III colon cancer patients when compared with open colectomy,” according to an analysis of data...

colorectal cancer

Use of Minimally Invasive Colorectal Cancer Surgery Increases at NCCN Centers, but Wide Variation Exists

A recent study on the use of minimally invasive surgery for colorectal cancer at National Comprehensive Cancer Network (NCCN) centers has found that although laparoscopic colectomy results in equivalent oncologic outcomes compared to open colectomy, its adoption nationally has been slow. An...

colorectal cancer

Adding Ziv-Aflibercept to FOLFIRI Results in Persistent Improvement in Overall Survival in Patients With Metastatic Colorectal Cancer

Patients with metastatic colorectal cancer showed a continued and persistent improvement over time in overall survival when they received ziv-aflibercept (Zaltrap) in addition to FOLFIRI (irinotecan, fluorouracil, leucovorin), reported by Ruff et al in the European Journal of Cancer. Survival was...

colorectal cancer

FOLFOXIRI/Bevacizumab Bests FOLFIRI/Bevacizumab in Metastatic Colorectal Cancer

Patients with untreated metastatic colorectal cancer who received FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) had improved survival compared to patients who received FOLFIRI (5-FU, leucovorin, irinotecan) plus bevacizumab in a phase III...

gynecologic cancers
colorectal cancer
head and neck cancer
kidney cancer
lung cancer
issues in oncology
bladder cancer
issues in oncology

14 Million Major Medical Conditions Attributable to Cigarette Smoking

At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...

colorectal cancer

Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer

The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who had disease progression on oxaliplatin-based chemotherapy persisted beyond median...

colorectal cancer
issues in oncology

Oncologists Respond Rapidly to Clinical Trial Evidence on Use of EGFR Inhibitors

Use of panitumumab (Vectibix) and cetuximab (Erbitux) in patients with metastatic colorectal cancer decreased significantly after the publication of clinical trial evidence that anti-EGFR antibodies should be restricted to wild-type KRAS tumors, subsequent ASCO guidelines recommending testing for...

colorectal cancer

ASCO 2014: Chemotherapy Plus Either Bevacizumab or Cetuximab Results in Similar Survival Benefits in Metastatic Colorectal Cancer

Bevacizumab (Avastin) plus chemotherapy and cetuximab (Erbitux) plus chemotherapy produced equal survival benefits for patients with metastatic colorectal cancer and no KRAS mutations, according to results from a large federally funded phase III study presented at the 2014 ASCO Annual Meeting...

colorectal cancer

ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors

Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...

Advertisement

Advertisement



Advertisement